Literature DB >> 26951629

Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment.

C Bender1, A Dimitrakopoulou-Strauss2, A Enk1, J C Hassel3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26951629     DOI： 10.1093/annonc/mdw128

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

Review 1.  Systemic Vasculitis Associated With Immune Check Point Inhibition: Analysis and Review.

Authors:  Teresa M Crout; Day S Lennep; Shweta Kishore; Vikas Majithia
Journal:  Curr Rheumatol Rep       Date:  2019-05-21       Impact factor: 4.592

2.  Vasculitis associated with immune checkpoint inhibitors-a systematic review.

Authors:  Anisha Daxini; Keri Cronin; Antoine G Sreih
Journal:  Clin Rheumatol       Date:  2018-06-19       Impact factor: 2.980

Review 3.  Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.

Authors:  Konstantinos Melissaropoulos; Kalliopi Klavdianou; Alexandra Filippopoulou; Fotini Kalofonou; Haralabos Kalofonos; Dimitrios Daoussis
Journal:  Int J Mol Sci       Date:  2020-05-11       Impact factor: 5.923

4.  Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade.

Authors:  Sara Valpione; Sandro Pasquali; Luca Giovanni Campana; Luisa Piccin; Simone Mocellin; Jacopo Pigozzo; Vanna Chiarion-Sileni
Journal:  J Transl Med       Date:  2018-04-11       Impact factor: 5.531
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.